The DREAMM-7 trial interim analysis revealed that belantamab mafodotin combined with bortezomib and dexamethasone (BVd) significantly improved overall survival (OS) in relapsed or refractory multiple myeloma patients compared to the daratumumab, bortezomib, and dexamethasone (DVd) combination. This positive OS data reinforces earlier findings from DREAMM-7 and DREAMM-8, which demonstrated improved progression-free survival (PFS) with belantamab mafodotin combinations. The trial focused on patients who had received at least one prior therapy and experienced disease progression.

The observed OS benefit with BVd, a significant reduction in the risk of death, offers new hope for patients who often face limited effective options after relapse or treatment resistance. The sustained survival advantage over time, coupled with improved MRD negativity rates, suggests a potential for deeper and more durable responses compared to existing standard-of-care treatments. This could lead to a shift in treatment paradigms for relapsed/refractory multiple myeloma. The positive OS data strengthens the potential for regulatory approvals, broadening access to this promising treatment option for patients worldwide. This is particularly important given that multiple myeloma often becomes resistant to existing therapies and new treatment options are critically needed.

The interim analysis, with a median follow-up of 39.4 months, showed a 42% reduction in the risk of death with BVd compared to DVd. While median OS was not reached in either arm, projected mOS was 84 months for BVd and 51 months for DVd. The BVd arm also demonstrated a statistically significant improvement in MRD negativity rates, further supporting its potential for durable responses. Safety data for the belantamab mafodotin regimen remained consistent with previous findings, with manageable and resolvable eye-related side effects.

Looking ahead, the positive OS data from DREAMM-7, along with other supportive trial results, positions belantamab mafodotin combinations for potential regulatory approvals in various regions. This advancement holds promise for transforming the treatment of relapsed/refractory multiple myeloma, providing patients with a new, effective therapeutic option that could significantly extend survival. The upcoming DREAMM-10 trial in newly diagnosed, transplant-ineligible patients will further explore the potential of belantamab mafodotin in earlier treatment settings. This continued research could expand the clinical benefit of this therapy to a broader range of multiple myeloma patients.

Source link: http://www.businesswire.com/news/home/20241209175925/en/Belantamab-Mafodotin-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse

Jon Napitupulu
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.